Radiochemicals for research and clinical use

BV Cyclotron VU is a global health science company that produces radiopharmaceuticals and radiochemicals for medical diagnostics and research. Located at the campus of VU University Medical Center in Amsterdam, Cyclotron VU produces GMP- compliant medical isotopes in state-of-the-art manufacturing facilities. These products are used daily by pharmaceutical and biotechnology companies, medical device manufacturers, hospitals, clinics, and research laboratories.

89Zr-PET using different mAbs to detect the effects of a HSP90 inhibitor in patients with metastatic breast cancer

2/9/2014: Clinical Cancer Research has recently published the results of a clinical trial on 89Zr-PET imaging in metastatic breast cancer, carried out in the Nuclear Medicine and Molecular Imaging Center at the University of Groningen (the Netherlands) and the Royal Marsden Hospital in London (United Kingdom). arrow

Everolimus decreases the uptake of 89Zr-bevacizumab by neuroendocrine tumors

5/7/2014: In a joint effort, researchers from various departments at the University of Groningen, the Netherlands, have recently shown that everolimus, a drug currently used in the treatment of diverse cancer types, reduces the uptake of 89Zr-labeled bevacizumab in patients with neuroendocrine tumors. arrow

Study harmonizes 89Zr-PET/CT performance in multicenter studies

13/2/2014: Researchers from the Medical Center of the VU University, Amsterdam, have recently carried out a multicenter evaluation to make the performance of PET/CT procedures using 89Zr uniform across different sites. Their positive results have just been published in the Journal of Nuclear Medicine. arrow

BV Cyclotron to produce 18F-NeuraCeq ™ for the Dutch market in cooperation with Piramal and IBA Molecular

23/1/2014: Piramal Imaging SA has recently announced the recommended approval of its investigational imaging agent NeuraCeq ™ (Florbetaben 18F) in the EU. For the Dutch market, BV Cyclotron will produce18F-NeuraCeq ™ in cooperation with Piramal and IBA Molecular. arrow

Upcoming Webinar: Advancing Discovery and Development of Biologics Through Non-Invasive Biodistribution Imaging

6/9/2013: On Tuesday, September 10, 2013, Dr. Maria Vosjan of BV Cyclotron VU, among others, will be a guest speaker at the Webinar Advancing Discovery and Development of Biologics Through Non-Invasive Biodistribution Imaging, hosted by Molecular Imaging, Inc. arrow

ARTFORCE - 1 Million Euro granted for production and delivery of 89Zr-radiolabeled antibodies

2/8/2013: Last week, researchers at the VU University Medical Center (VUmc) in Amsterdam received a 1-million Euro funding for a multicenter trial in head and neck cancer patients. The funding, granted by KWF/Alpe d’HuZes, will be used by the VUmc to produce 89Zr-radiolabeled antibodies for leading oncological centers in Europe. arrow